CDCA2 (Cell Division Cycle Associated 2) is a key regulator of chromosome 8 and cell cycle progression that plays critical roles in mitosis and DNA damage response. The protein functions by recruiting protein phosphatase 1 (PP1-gamma) to chr8 during anaphase to dephosphorylate substrates and maintain chromosome 8 1. CDCA2 is involved in multiple cellular processes including chromosome 8, decondensation, nuclear envelope reassembly, and microtubule assembly 2. The gene participates in several signaling pathways, notably the PI3K/Akt and p53 pathways 2. CDCA2 overexpression is strongly associated with cancer development and progression across multiple tumor types. In oral squamous cell carcinoma, CDCA2 upregulation prevents G1 phase arrest and apoptosis by antagonizing ATM-dependent signaling 1. In melanoma, CDCA2 promotes progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A 3. In hepatocellular carcinoma, CDCA2 enhances malignant behaviors through activation of the AKT-mTOR pathway 4. Clinically, elevated CDCA2 expression correlates with poor prognosis, larger tumor size, and advanced TNM staging across various cancers 21, making it a promising biomarker for diagnosis and potential therapeutic target.